20/20 Gene Systems Biotech SeedInvest/Crowdcube Campaign Now 1090%+ Overfunding

Machine learning, algorithms, early cancer detection, successful intervention? 20/20 GeneSystems, a digital diagnostics company with the core mission of reducing cancer mortality in the U.S. and around the world through early detection, sells what it believes to be the first multi-cancer blood test powered by real-world data and machine learning algorithms.

The US biotech company originally synced with SeedInvest and Crowdcube to raise £348,710 via Reg A+.  Now, with  19 days remaining on the equity crowdfunding campaign, over 232 investors have raised over £3,813,740 for 15.92% equity in 20/20. The campaign is currently overfunding by more than 1092%.

Seriously Overfunding @2020Gene @SeedInvest @Crowdcube #rega+ #crowdfunding #cancer #earlydetection Click to Tweet

Early detection substantially improves outcomes for many cancer types. Helmed by Founder and CEO Jonathan Cohen, in late 2018, 20/20 introduced in both the U.S. and East Asia a blood test for the early detection of multiple cancers called OneTest™.

“We believe this product is the world’s first cancer screening blood test powered by machine learning algorithms built from data from tens of thousands of individuals screened yearly in a real-world clinical setting. Tests built with data from individuals tested before developing symptoms of cancer tend to be more reliable for screening than blood samples from patients acquired post diagnosis,” averred the campaign. “Blood testing to screen for many different cancers is very common throughout East Asia. Every day millions of individuals in Japan, Korea, and China visit “Health Check Centers” where they are tested with many of the same biomarkers that are part of OneTest. The foundation of our product is based on this East Asian testing paradigm, but our proprietary algorithms substantially improve the accuracy of standard biomarker testing by reducing the number of missed cancers by more than half.”

Launched in 2008, 20/20 has also targeted East Asia, specialty health check-up clinics throughout Europe, including the U.K., and the Middle East to offer its OneTest Cloud Analytics software.

For more 20/20 GeneSystems campaign details and updates, please click here.


Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote



Send this to a friend